Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced new pre-clinical data on its drug Ampligen as part of a combination therapy for melanoma treatment. The study, published in the journal Vaccines, shows that combining dendritic cell-based vaccines with anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.
Dr. David Strayer, AIM's Medical Officer, stated that this data further demonstrates Ampligen's therapeutic potential when used with dendritic-cell vaccines, anti-PD-L1 checkpoint inhibitors, or in combination with both. The company believes this supports their ongoing development of Ampligen as an anti-tumor therapy.
AIM ImmunoTech announced the release of a new CEO Corner segment on their website. CEO Thomas Equels provided updates on the Phase 1b/2 DURIPANC study for a combination therapy of Ampligen and AstraZeneca's Imfinzi targeting late-stage pancreatic cancer. Additionally, the company reported a stockholders' equity of $6.9 million as a result of recent financings. The full CEO Corner segment can be accessed on the company's website.
AIM ImmunoTech will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET. CEO Thomas K. Equels will deliver an elevator pitch outlining the company's upcoming milestones. Investors can submit questions live during the event, with responses provided within the time constraints. The live video webcast will be available on AIM ImmunoTech's website, with a replay accessible for 90 days.
AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in the Virtual Investor Lunch Break Series on June 5, 2024, at 12:00 PM ET. During the event, Mr. Equels will give a corporate overview and discuss the company's business outlook. Attendees can submit questions live, which Mr. Equels will address. The live webcast will be available on the company’s website, and a replay will be accessible for 90 days two hours after the presentation.
AIM ImmunoTech announced a $2 million registered direct offering with a single institutional investor. The deal includes the purchase of 5,640,958 shares of common stock at $0.363 per share and unregistered Class A and Class B warrants to buy an additional 5,640,958 shares each. The Class A warrants expire 18 months from issuance, while Class B warrants expire in five years. Maxim Group acts as the sole placement agent. The gross proceeds are around $2 million before fees and expenses. The offering is made under a shelf registration statement effective since February 4, 2022.
AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.
AIM ImmunoTech reported its Q1 2024 financial results, showing a net loss of $5.8 million, or $0.12 per share, compared to $3.7 million, or $0.08 per share, in Q1 2023. Cash reserves are at $10.9 million. The company highlighted progress in its Ampligen clinical programs, including positive interim data in ovarian cancer and the completion of cGMP manufacturing of 9,000 vials. AIM also announced that the first dose in a Phase 1b/2 study for late-stage pancreatic cancer was well-tolerated. Upcoming milestones include final data for Post-COVID Conditions in Q2 2024. AIM will host a conference call today, May 16, 2024, to discuss these results.
AIM ImmunoTech Inc. will hold a conference call and webcast on May 16, 2024, to discuss Q1 2024 operational and financial results. The call will be led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer. Participants can join via phone or webcast on the aimimmuno.com website.
AIM ImmunoTech Inc. has completed cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), a dsRNA product candidate for cancer, viral diseases, and immune disorders. CEO Thomas K. Equels emphasized the importance of this milestone for the company's development and commercial strategies, highlighting ongoing clinical trials for solid tumors.
AIM ImmunoTech Inc. announced positive results in testing Ampligen and Imfinzi in late-stage pancreatic cancer treatment. The combination was well-tolerated with no severe adverse events. The next safety cohort will start escalated dosing soon. Subjects will be monitored for response for up to 48 weeks.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
